KRAS and cancer: Finally, Trametinib (MEKi) (Supplementary Fig. 9d) and SCH772984 (ERKi) (Supplementary Fig. 9e) alone modestly decreased proliferation in MEFs expressing KRAS mutants and selected cancer cell lines with KRAS mutations.